Effects of Oestrogens, Orchidectomy and Cyproterone Acetate on Salt and Water
Metabolism in Carcinoma of the Prostate

E. Varenhorst; B.E. Karlberg; L. Wallentin; B. Wranne

doi:10.1159/000473226

Effects of Oestrogens, Orchidectomy and Cyproterone Acetate on Salt and Water Metabolism in Carcinoma of the Prostate

European Urology ◽

10.1159/000473226 ◽

1981 ◽

Vol 7 (4) ◽

pp. 231-236 ◽

Cited By ~ 5

Author(s):

E. Varenhorst ◽

B.E. Karlberg ◽

L. Wallentin ◽

B. Wranne

Keyword(s):

Cyproterone Acetate ◽

Water Metabolism ◽

Carcinoma Of The Prostate

Download Full-text

The effects of orchiectomy, oestrogens and cyproterone-acetate on the antithrombin-III concentration in carcinoma of the prostate

Urological Research ◽

10.1007/bf00256835 ◽

1981 ◽

Vol 9 (1) ◽

Cited By ~ 13

Author(s):

Eberhard Varenhorst ◽

Lars Wallentin ◽

Bo Risberg

Keyword(s):

Cyproterone Acetate ◽

Antithrombin Iii ◽

Carcinoma Of The Prostate ◽

Antithrombin Iii Concentration

Download Full-text

Cyproterone Acetate in the Treatment of Advanced Carcinoma of the Prostate

The Journal of Urology ◽

10.1016/s0022-5347(17)60128-9 ◽

1973 ◽

Vol 110 (1) ◽

pp. 106-108 ◽

Cited By ~ 54

Author(s):

Robert B. Smith ◽

Patrick C. Walsh ◽

Willard E. Goodwin

Keyword(s):

Cyproterone Acetate ◽

Advanced Carcinoma ◽

Carcinoma Of The Prostate

Download Full-text

Palliative Effect of Cyproterone Acetate in Carcinoma of the Prostate with Widespread Metastatic Bone Disease

British Journal of Urology ◽

10.1111/j.1464-410x.1980.tb03072.x ◽

1980 ◽

Vol 52 (5) ◽

pp. 402-402 ◽

Cited By ~ 3

Author(s):

M. FOX ◽

J. C. HAMMONDS

Keyword(s):

Bone Disease ◽

Cyproterone Acetate ◽

Metastatic Bone Disease ◽

Carcinoma Of The Prostate

Download Full-text

Cyproterone Acetate Lead-In Prevents Initial Rise of Serum Testosterone Induced by Luteinizing Hormone-Releasing Hormone Analogs in the Treatment of Metastatic Carcinoma of the Prostate

European Urology ◽

10.1159/000472667 ◽

1986 ◽

Vol 12 (6) ◽

pp. 400-402 ◽

Cited By ~ 33

Author(s):

L. Boccon-Gibod ◽

M.H. Laudat ◽

M.A. Dugue ◽

A. Steg

Keyword(s):

Luteinizing Hormone ◽

Cyproterone Acetate ◽

Serum Testosterone ◽

Metastatic Carcinoma ◽

Luteinizing Hormone Releasing Hormone ◽

Releasing Hormone ◽

Carcinoma Of The Prostate ◽

Initial Rise ◽

Acetate Lead ◽

Hormone Analogs

Download Full-text

Long-term results of an LH-RH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade with pre-medicated cyproterone acetate

Endocrine Management of Prostatic Cancer ◽

10.1515/9783110853674-014 ◽

1988 ◽

pp. 127-137 ◽

Cited By ~ 2

Author(s):

G. H. Jacobi

Keyword(s):

Cyproterone Acetate ◽

Long Term Results ◽

Carcinoma Of The Prostate ◽

Lh Rh ◽

Androgen Blockade

Download Full-text

The Final Analysis of the EORTC Genito-Urinary T ract Cancer Co-Operative Group Phase III Clinical Trial (Protocol 30805) Comparing Orchidectomy, Orchidectomy plus Cyproterone Acetate and Low Dose Stilboestrol in the Management of Metastatic Carcinoma of the Prostate

European Urology ◽

10.1159/000475067 ◽

1995 ◽

Vol 28 (4) ◽

pp. 272-283 ◽

Cited By ~ 65

Author(s):

M.R.G. Robinson ◽

P.H. Smith ◽

B. Richards ◽

D.W.W. Newling ◽

M. de Pauw ◽

...

Keyword(s):

Clinical Trial ◽

Cyproterone Acetate ◽

Low Dose ◽

Final Analysis ◽

Metastatic Carcinoma ◽

Phase Iii ◽

Trial Protocol ◽

Phase Iii Clinical Trial ◽

Clinical Trial Protocol ◽

Carcinoma Of The Prostate

Download Full-text

Effects of Cyproterone Acetate and a Long-Acting LHRH Analogue on Serum Lipoproteins in Patients with Carcinoma of the Prostate

Journal of the Royal Society of Medicine ◽

10.1177/014107688607900407 ◽

1986 ◽

Vol 79 (4) ◽

pp. 210-211 ◽

Cited By ~ 14

Author(s):

R B Paisey ◽

C Kadow ◽

C Bolton ◽

M Hartog ◽

J C Gingell

Keyword(s):

Cyproterone Acetate ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Hdl Cholesterol ◽

Serum Lipoproteins ◽

Group Iii ◽

Lhrh Analogue ◽

Carcinoma Of The Prostate ◽

Group I ◽

Long Acting

Fasting serum lipoproteins were measured in 10 untreated patients with carcinoma of the prostate (Group I), 17 patients with non-malignant urological disorders (Group II), and 12 patients on cyproterone acetate (Group III) and 5 on a long-acting luteinizing hormone-releasing hormone (LHRH) analogue (Group IV) for at least 2 months for carcinoma of the prostate. Total high-density lipoprotein (HDL) cholesterol levels were significantly lower in patients in Group III than all the other groups. Very low-density lipoprotein (VLDL) triglyceride levels were significantly higher in patients in Group III than those in Groups II and IV. These results suggest a potentially adverse effect of cyproterone acetate, but not of the long-acting LHRH analogue, on serum lipids, which is likely to be of relevance only in younger patients.

Download Full-text